Bristol's New CSO Lynch Defends Lung Cancer Plans, Proclaims R&D Priorities

 
• By Emily Hayes

Opdivo first-quarter sales were still strong at $1.1bn, largely driven by lung cancer use and helping to drive overall performance, but potential approval of Merck's competing Keytruda with chemotherapy in first-line lung cancer is right around the corner.

BMY Chief Scientific Officer Thomas Lynch
Bristol's Chief Scientific Officer Thomas Lynch • Source: Bristol-Myers Squibb

More from Immuno-oncology

More from Anticancer